X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Cash received from principal payments made on loans related to operating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Contract and other revenue. No definition available.
|
X | ||||||||||
- Definition Represents the eligible milestone payments receivable, if the company re-acquired cardiovascular and/or diabetes rights for use in the United States. No definition available.
|
X | ||||||||||
- Definition Represents eligible milestone payments receivable after amendments, if the company re-acquired cardiovascular and/or diabetes rights for use in the United States. No definition available.
|
X | ||||||||||
- Definition Represents eligible milestone payments receivable, if the company did not re-acquire those rights. No definition available.
|
X | ||||||||||
- Definition Represents Eligible milestone payments receivable, if the company did not re-acquire those rights after amendment. No definition available.
|
X | ||||||||||
- Definition The aggregate amount of future initial clinical research and development expenses that will be funded by the counterparty. No definition available.
|
X | ||||||||||
- Definition Upfront payment received. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|